You have read all your free articles, to continue reading subscribe to read the rest of this content.
Swedish drug development company Modus Therapeutics has had a busy year, and 2019 could take them one step closer to having sevuparin on the market.
In 2016 the clinical-stage drug development and Karolinska Development portfolio company Dilaforette Holding changed its name to Modus Therapeutics
Related Posts
Nordic Nanovector has provided an update on PARADIGME, its Phase 2b trial of Betalutin in 3rd-line relapsed and anti-CD20 refractory follicular lymphoma. Following a comprehensive review and independent data evaluation of PARADIGME and a subsequent request for regulatory agency interaction, the BAlready a subscriber Login You have read all your…
Orion is developing an immuno-oncology (IO) drug discovery platform in the national research and innovation consortium Cancer IO. The national research and innovation project Cancer IO started in May as a part of Business Finland’s Personalized Health Program. The project will develop new solutAlready a subscriber Login You have read…
The Danish Life Science Cluster and the Ministry of Foreign Affairs of Denmark have established a new partnership to create easier access to China for Danish companies within medtech, healthtech and rehabilitation – with a special focus on a designated specialty medical zone. Danish Life SciencAlready a subscriber Login You…
Menarini Asia-Pacific, a member of the Menarini Group, has been granted the exclusive rights to market and sell Moberg Pharma’s Kerasal Nail on the Chinese market. Kerasal Nail is a non-prescription product for the treatment of discoloured and deformed nails resulting from fungal infection or Already a subscriber Login You have…